Form 4: Agios Pharmaceuticals Executive Sells Shares

Agios Pharmaceuticals Chief Legal Officer James William Burns reported a transaction involving the sale of common stock to cover tax withholding obligations related to vested performance share units.

Summary

• James William Burns, Chief Legal Officer at Agios Pharmaceuticals, Inc., engaged in a stock transaction on April 2, 2026.
• The transaction involved the sale of 3,280 shares of common stock at a price of $34.71 per share.
• Additionally, 8,500 shares were acquired and immediately disposed of, with no cost basis indicated, to cover tax withholding obligations upon the vesting of performance share units (PSUs).
• These PSUs were granted on March 1, 2024, and vest based on achieving specific regulatory and commercial milestones.
• The regulatory milestone was met on April 2, 2026, leading to the vesting of 50% of the underlying shares.
• Following these transactions, Mr. Burns beneficially owns 49,306 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the primary transaction is a standard insider stock sale for tax withholding purposes executed under a pre-arranged plan, rather than a reflection of negative or positive company performance.

Positives

• Achievement of a specified regulatory milestone for performance share units, indicating progress in the company's development pipeline.
• The transaction was executed under a Rule 10b5-1(c) plan, suggesting pre-planned and compliant trading activity by management.

Negatives

• Sale of company stock by a key executive, which could be perceived negatively by the market, although it was for tax withholding.
• The sale of 3,280 shares at $34.71 per share represents a reduction in the executive's direct holdings.

Risks

• The vesting of PSUs is contingent on achieving specific regulatory and commercial milestones, which carry inherent development and market risks.
• Future vesting of the remaining 50% of PSUs depends on achieving a specified commercial milestone, which is subject to market acceptance and competitive pressures.

Future Outlook

The remaining 50% of the performance share units are subject to vesting upon the achievement of a specified commercial milestone, the details and timeline of which are not provided in this filing.

Management Comments

• The transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act.
• Such instructions were included in the reporting person's performance share unit agreement dated March 1, 2024.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions. The use of a Rule 10b5-1(c) plan by Agios Pharmaceuticals' Chief Legal Officer indicates a structured approach to managing personal stock holdings, often employed to avoid perceptions of insider trading.

Stakeholder Impact

• Shareholders: The sale of shares by an executive, even for tax purposes, may lead to minor short-term market perception shifts, though the Rule 10b5-1(c) plan mitigates concerns about insider trading.
• Employees: The achievement of a regulatory milestone for PSUs could be seen as a positive indicator for employees involved in the relevant development efforts.
• Management: The transaction reinforces the company's adherence to established corporate governance practices regarding executive compensation and stock transactions.

Next Steps

• Delivery of vested shares to the reporting person within three business days after vesting.
• Monitoring for the achievement of the specified commercial milestone for the remaining 50% of PSUs.

Key Dates

Keywords

Form 4, SEC Filing, Agios Pharmaceuticals, AGIO, Insider Trading, Stock Transaction, Performance Share Units, Vesting, Tax Withholding, Rule 10b5-1, James William Burns, Chief Legal Officer